TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03560050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition assistance
Description: Participating family child care home providers in and around the Oklahoma City (OKC) area will be randomized to either the Nutrition (n=26), or an environmental health comparison group (n=26). Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children's environmental health
Description: Participating family child care home providers in and around the OKC area will be randomized to either the Nutrition (n=26), or an environmental health intervention (n=26) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Intervention will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
Study: NCT01764568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Description: The metacognitive group training program that will form the basis of the 16 session MCT intervention has been described in previous research (Moritz \& Woodward 2007a; Moritz \& Woodward 2007b; Moritz 2011) and can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of two 8-module cycles occurring twice a week for 8 weeks, for a total of 16 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects. Subjects will be able to attend the alternate (Cognitive Remediation) group after completion of the MCT group if they wish.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Description: The CR group will use a computerized cognitive remediation program that has been used with schizophrenia patients, Scientific Brain Training Pro (SBT Pro; Vianin et al, 2010). Modules focus on attention, working memory, verbal memory, and planning and reasoning. Each session will incorporate psycho-educational group discussion of strategies, and individual work through exercises on personal tablet computers and personalized level of difficulty. The CR treatment will take place twice per week for 8 weeks, for a total of 16 sessions. Groups will consist of 4-10 subjects. Subjects will be able to attend MCT after completion of CR if they wish.
Study: NCT03960294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOZE Sleep App
Description: DOZE is an evidence-based cognitive behavioural therapy for insomnia app created specifically for use with adolescents and young adults.
Study: NCT03206190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPRS Score and clinical signs
Description: Patients will clinically characterized by using the SPRS Score and the inventory V3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPRS Score and clinical signs
Description: Patients will clinically characterized by using the SPRS Score and the inventory V3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPRS Score and clinical signs
Description: Patients will clinically characterized by using the SPRS Score and the inventory V3

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognition Testing using CANTAB
Description: Patients will be tested using the CANTAB

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognition Testing using CANTAB
Description: Patients will be tested using the CANTAB
Study: NCT02477553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DA - Quantitative

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DA - Verbal
Study: NCT01017445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boonme stick exercise
Description: individual exercise daily
Study: NCT04253457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1ml of triamcinolone (40mg/1ml)
Description: Single injection of 1ml of triamcinolone (40mg/1ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1ml of triamcinolone (40mg/1ml)
Description: Single injection of 1ml of triamcinolone (40mg/1ml)
Study: NCT03770104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ETT insertion depth using Spanish recommendations
Description: Infants included in this assignment group will be intubated using the formula 5.5 plus weight, when requiring oral intubation in the delivery room.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ETT insertion depth using international recommendations
Description: Infants included in this assignment group will be intubated using the formula 6 plus weight, when requiring oral intubation in the delivery room.
Study: NCT02472236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: 200µg,injected subcutaneously,once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: 0.5mg,oral,two times.
Study: NCT00952614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fluocinolone acetonide (Retisert Implant, Bausch and Lomb)
Description: sustained release device consisting of 0.59 mg of fluocinolone acetonide
Study: NCT04231916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal imaging device
Study: NCT02364440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultherapy™ System
Description: Subjects will receive 20 lines Ultherapy™ System Treatment over their right and left hand with 1.5 and 3.0 probe respectively
Study: NCT03380767

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trauma-induced coagulopathy treatment
Description: Transfusion as needed according to the assay methodology

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trauma-induced coagulopathy treatment
Description: Transfusion as needed according to the assay methodology
Study: NCT03464149

Intervention type: DIAGNOSTIC_TEST
Intervention: One armed study, blood from each patient is analysed by four assays ( two 3rd generation and two 2nd generation assays)
Description: Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)
Study: NCT03358940

Intervention type: OTHER
Group type: OTHER
Intervention: urine collection
Description: For patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection the day of the inclusion. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
Study: NCT03302286

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Heart-lung machine primining solution which includes Mannitol
Description: This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Heart-lung machine primining solution which does not include Mannitol
Description: This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
Study: NCT05777239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Implant Approach for Crestal Sinus Elevation
Description: Crestal Sinus Elevation by elevating the sinus membrane with a blunt ended dental implant approach
Study: NCT03921333

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose response efficacy of plant extracts
Description: 300mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Middle dose response efficacy of plant extracts
Description: 500mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Dose response efficacy of plant extracts
Description: 700mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose microcrystalline
Study: NCT02007564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIFE Intervention
Description: RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
Study: NCT04582110

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography
Description: Each subject underwent Optical coherence tomography angiography (a non-invasive, fast, diagnostic imaging technique)

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography
Description: Each subject underwent Optical coherence tomography angiography (a non-invasive, fast, diagnostic imaging technique)
Study: NCT03841734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment
Description: 8 patients will be treat with bosentan at 145 mg per day during 14 days
Study: NCT00849108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS747158
Description: dosages at rest and at stress were not to exceed a total of 14 mCi.~Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.~Cohort 2: Patients to recieve IV bolus injections of BMS747158:~For the Pharmacologic (Adenosine) Stress:~* Doses at rest were to range between 2.9 and 3.4 mCi.~* Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~* Doses at rest were to range between 1.7 and 2.0 mCi.~* Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS747158
Description: dosages at rest and at stress were not to exceed a total of 14 mCi.~Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.~Cohort 2: Patients to recieve IV bolus injections of BMS747158:~For the Pharmacologic (Adenosine) Stress:~* Doses at rest were to range between 2.9 and 3.4 mCi.~* Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~* Doses at rest were to range between 1.7 and 2.0 mCi.~* Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi.
Study: NCT03468894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill desk walking
Description: See intervention arm description
Study: NCT02437370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study: NCT00751348

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PriorixTM
Description: Subcutaneous administration in left upper arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VarilrixTM
Description: Subcutaneous administration in right upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix-Tetra®
Description: Subcutaneous injection in left upper arm
Study: NCT03084588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone
Description: Patients will be given methadone at induction of anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: Patients will be given an interscalene block prior to induction of anesthesia
Study: NCT02258100

Intervention type: OTHER
Intervention: Electronic Medical Record
Description: Advent of EMR use for documentation of anesthetic care
Study: NCT00006101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eflornithine
Description: Take 500mg of DFMO per day for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take placebo per day for 12 months
Study: NCT03096132

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Behavioral Treatment
Description: Treatment includes 20 90 minute visits over 6 months which include 60 min parent and child separate groups and 30 min behavioral coaching. FBT includes information regarding nutrition and physical activity, as well as behavior therapy skills, including parenting skills, self-monitoring, problem solving skills, motivation systems, emotional regulation, stress management, stimulus control, and relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help Fam. Based Bx Treatment
Description: Treatment includes 14 20 minute visits over 6 months. gshFBT is delivered to parent/child dyads and includes the same content in the FBT groups but it is provided in a manual. The 20-minute visits focus on clarifying information in the manuals, collecting weight and self-monitoring logs, and problem solving any barriers to implementation.
Study: NCT03652610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)
Description: Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed GSK MenACWY vaccine (Menveo)
Description: Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
Study: NCT02648841

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Concurrent Chemo-radiotherapy
Description: Adjuvant concurrent chemo-radiotherapy will be given to the patients in the Experimental group after 4-6 cycles of SOX chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy for active comparator group
Description: 8 cycles of SOX adjuvant chemotherapy will be given to the patients in the active comparator group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for experimental group
Description: 6 cycles of SOX adjuvant chemotherapy will be given to the patients in the experimental group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
Study: NCT02131454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhalation technique training
Description: Training in inhalation technique in asthmatics and COPD patients
Study: NCT02613052

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 10 mL of normal saline agitated prior to IV administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human albumin
Description: 10 mL of 5% albumin agitated prior to IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human albumin and propofol
Description: 7 mL of 5% albumin mixed with 3 mL of propofol (10 mg/mL) agitated together prior to IV administration
Study: NCT02815345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhinometry
Description: An acoustic rhinometry device will be used to evaluate the area and the volume of the nasal cavities. Both nasal cavities will be measured except for patients with nasogastric tube.
Study: NCT03776565

Intervention type: OTHER
Intervention: Ultrasound
Description: Ultrasound of antrum of stomach

Intervention type: OTHER
Intervention: Ultrasound
Description: Ultrasound of antrum of stomach
Study: NCT02006641

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, matching placebo capsules, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine
Description: Once daily, encapsulated tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine
Description: Once daily, encapsulated tablets, orally
Study: NCT02735551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long Acting Reversible Contraception (LARC)
Description: Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral for Long Acting Reversible Contraception (LARC)
Description: Referral to local clinic for LARC placement of choice (Mirena, Skyla, Paragard, Implanon, etc.)
Study: NCT03206190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognition Testing using CANTAB
Description: Patients will be tested using the CANTAB
Study: NCT02437370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT03206190

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture and blood draw
Description: Biomaterial will be collected (not obligate) to compare e.g. Nfl levels in serum and CSF
Study: NCT02735551

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prescription for Short-Acting Hormonal Contraception
Description: Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice
Study: NCT03165110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Onyx BG Meter / App System
Description: Subjects with diabetes used the Onyx BG Meter / App System at home and assessed the features of the App.
Study: NCT02846207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqi huoxue
Description: Buyang Huanwu demolition, which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqi group
Description: Astragalus 60g.Oral administration, twice one day, for 12weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huoxue group
Description: Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dextrin,oral administration, twice one day, for 12weeks.
Study: NCT03270384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urotronic Drug Coated Balloon (DCB)
Description: The Urotronic Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
Study: NCT04017299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHOISIR
Description: Every patient will evaluate each device after 15 minutes of distraction once or twice a day according to the patient's wishes.

Intervention type: OTHER
Group type: OTHER
Intervention: CHOISIR
Description: Every patient will evaluate each device after 15 minutes of distraction once or twice a day according to the patient's wishes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHOISIR
Description: Every patient will evaluate each device after 15 minutes of distraction once or twice a day according to the patient's wishes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHOISIR
Description: Every patient will evaluate each device after 15 minutes of distraction once or twice a day according to the patient's wishes.
Study: NCT00696241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and olmesartan
Description: Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and olmesartan
Description: Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and olmesartan
Description: Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
Study: NCT00696241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.
Study: NCT02730663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Niti-S SPAXUS Stent
Description: Endoscopic Ultrasound-Guided Transluminal drainage
Study: NCT03447743

Intervention type: DRUG
Group type: OTHER
Intervention: XR-NTX community location
Description: XR-NTX will be administered at the local health care clinic
Study: NCT03690609

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CytoQuel
Description: 3 capsules daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CytoQuel
Description: 2 capsules twice daily.